Hurwitz 2007 USA.

Methods	Country: USA Setting: university clinic Duration of recruitment: June 2001 to July 2005 Duration of follow‐up: 9 months Design: randomized placebo controlled trial
Participants	Inclusion criteria: aged 18 to 55 years; no history of major systemic disorders related to HIV; premenopausal and not pregnant Exclusion criteria: on treatment for chronic conditions; selenium deficient Participants randomized: 310 Mean age = 40.5 years 179 male and 86 female Loss to follow‐up/withdrawal: 88 Exclusions postrandomization: 48 pretreatment
Interventions	Intervention: selenium (200 µg) Control: placebo Duration: daily for 9 months
Outcomes	Primary outcomes Viral load CD4 count Serum selenium
Adverse events	None
Notes	Participants on ART: 105/141 (74%) in selenium group; 87/121 (72%) in placebo group Preliminary analysis at 9 months of an 18‐month trial Source of funding: National Institutes of Health
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial used computerized block randomization.
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment used.
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants and investigators were blinded.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	There were high unexplained losses to follow‐up, which were balanced between groups. The trial authors performed imputational analyses.
Selective reporting (reporting bias)	High risk	The trial only reported data on main study outcomes for subgroups of participants (selenium responding versus non‐responding participants).
Other bias	Low risk	The trial authors declared they had no conflicts of interest.